Compare Agilent Technologies Inc (A) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs iShares MSCI India ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while iShares MSCI India ETF trades at $50.05. The key difference: Agilent Technologies Inc pays a 0.69% dividend while iShares MSCI India ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| A | INDA | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $157.20 | $55.29 |
52-Week Low | $110.24 | $45.42 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
INDA, trading at $50.39 with a 0.54% daily gain, shows a bullish technical outlook supported by moving averages, though RSI levels indicate potential overbought conditions near-term. The ETF tracks India's equity market, the world's fastest-growing large economy, which expanded 7.8% in Q1 2026 (CNBC, June 5, 2026). Recent news highlights foreign capital rotation away from AI-heavy Asian markets, with India facing sector-specific headwinds in pharmaceuticals and IT.
The outlook remains positive given India's robust economic growth, but risks include U.S. tariff uncertainty, Middle East shipping disruptions impacting exports (Reuters, August 4, 2026), and El Niño monsoon concerns. Investor sentiment is mixed amid foreign outflows, yet structural growth opportunities support long-term potential. Key watchpoints are earnings delivery from underlying holdings and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
